SCHEMBL1822004

SCHEMBL1822004

COC(=O)C(CC(=O)O)c1c([N+](=O)[O-])cc(F)cc1[N+](=O)[O-]

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.42
TSHR P16473 1/20 0.42
ALDH1A1 P00352 3/20 0.40
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 1/20 0.36
TTR P02766 1/20 0.36
PDGFRB P09619 1/20 0.35
FGFR1 P11362 1/20 0.35
PDGFRA P16234 1/20 0.35
FLT1 P17948 1/20 0.35
FGFR3 P22607 1/20 0.35
KDR P35968 1/20 0.35
HCAR3 P49019 1/20 0.35
KMT2A Q03164 2/20 0.35
PKM P14618 1/20 0.35
HTT P42858 1/20 0.34
POLB P06746 1/20 0.34
MEN1 O00255 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1822015 0.86 MAPT (0.41) ALDH1A1SMN1; SMN2MAPTPDGFRBFGFR1
SCHEMBL1821387 0.80 ALDH1A1 (0.53) ALDH1A1MAPTTTRPDGFRBFGFR1
SCHEMBL1817535 0.70 AKR1C3 (0.40) TSHRALDH1A1SMN1; SMN2MAPTTTR
SCHEMBL1819883 0.70 TTR (0.41) CYP1A2TSHRALDH1A1SMN1; SMN2MAPT
SCHEMBL12627940 0.69 ALDH1A1 (0.48) TSHRALDH1A1SMN1; SMN2MAPTKMT2A
SCHEMBL12580606 0.69 ALDH1A1 (0.54) TSHRALDH1A1SMN1; SMN2MAPTKMT2A
SCHEMBL26931027 0.69 ALDH1A1 (0.44) ALDH1A1MAPTKMT2AHTTPOLB
SCHEMBL30660344 0.69 ALDH1A1 (0.44) ALDH1A1MAPTKMT2AHTTPOLB
SCHEMBL4319842 0.68 CYP1A2 (0.49) CYP1A2ALDH1A1SMN1; SMN2MAPTTTR
SCHEMBL3363358 0.68 ALDH1A1 (0.64) ALDH1A1MAPTKMT2APKMMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951042-B1 SPIROLACTAM TRICYCLIC CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2012-10-10 EP disclosed
EP-1951051-B1 SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2012-10-03 EP disclosed
US-7968540-B2 Spirohydantoin tricyclic CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-06-28 US disclosed
US-7947677-B2 Spirolactam tricyclic CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-05-24 US disclosed
US-20090281080-A1 Spirohydantoin Tricyclic CGRP Receptor Antagonists MERCK SHARP & DOHME LLC 2009-11-12 US disclosed
US-20090105219-A1 Spirolactam Tricyclic CGRP Receptor Antagonists MERCK SHARP & DOHME LLC 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105219-A1 Spirolactam Tricyclic CGRP Receptor Antagonists BDKRB1, CALCRL, BDKRB2 CYP1A2 1242/4885TSHR 547/4885ALDH1A1 962/4885
US-20090281080-A1 Spirohydantoin Tricyclic CGRP Receptor Antagonists BDKRB1, BDKRB2, CCKBR CYP1A2 967/4885TSHR 356/4885ALDH1A1 1140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.